Current Screening Tests/Biomarkers for Alzheimer's Disease: Implications for Clinicians.
作者信息
Patel Vimita, Grossberg George
机构信息
Resident in the Department of Psychiatry and Behavioral Neuroscience.
Henry and Amelia Nasrallah Professor, and Director, Division of Geriatric Psychiatry, Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri.
出版信息
Mo Med. 2024 Jul-Aug;121(4):271-275.
Abstract
摘要
相似文献
1
Current Screening Tests/Biomarkers for Alzheimer's Disease: Implications for Clinicians.
Mo Med. 2024 Jul-Aug;121(4):271-275.
2
Relationship of dementia screening tests with biomarkers of Alzheimer's disease.
Brain. 2010 Nov;133(11):3290-300. doi: 10.1093/brain/awq204. Epub 2010 Sep 7.
3
When is Alzheimer's not dementia-Cochrane commentary on The National Institute on Ageing and Alzheimer's Association Research Framework for Alzheimer's Disease.
Age Ageing. 2019 Mar 1;48(2):174-177. doi: 10.1093/ageing/afy167.
4
Current opinion neurology: visual pathway biomarkers in Alzheimer's disease.
Curr Opin Neurol. 2020 Feb;33(1):79-86. doi: 10.1097/WCO.0000000000000788.
5
REAL AD-Validation of a realistic screening approach for early Alzheimer's disease.
Alzheimers Dement. 2024 Nov;20(11):8172-8182. doi: 10.1002/alz.14219. Epub 2024 Sep 23.
6
Language and Meaning: Asymptomatic Alzheimer's Disease in the Clinic and Society.
J Alzheimers Dis. 2024;99(2):489-492. doi: 10.3233/JAD-240195.
7
The ROSAS Cohort: A Prospective, Longitudinal Study of Biomarkers for Alzheimer's Disease. Strategy, Methods and Initial Results.
J Prev Alzheimers Dis. 2017;4(3):183-193. doi: 10.14283/jpad.2017.8.
8
Challenges in the practical implementation of blood biomarkers for Alzheimer's disease.
Lancet Healthy Longev. 2024 Oct;5(10):100630. doi: 10.1016/j.lanhl.2024.07.013. Epub 2024 Oct 3.
9
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
10
Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease.
Brain. 2023 Feb 13;146(2):690-699. doi: 10.1093/brain/awac128.
本文引用的文献
1
APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.
Nat Med. 2024 May;30(5):1284-1291. doi: 10.1038/s41591-024-02931-w. Epub 2024 May 6.
2
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.
Alzheimers Dement. 2024 May;20(5):3179-3192. doi: 10.1002/alz.13764. Epub 2024 Mar 16.
3
Lecanemab in Early Alzheimer's Disease.
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
4
Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
Alzheimers Dement. 2023 May;19(5):1913-1924. doi: 10.1002/alz.12841. Epub 2022 Nov 12.
5
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Alzheimers Dement. 2023 Apr;19(4):1227-1233. doi: 10.1002/alz.12748. Epub 2022 Aug 15.
6
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease.
Nat Med. 2022 Sep;28(9):1797-1801. doi: 10.1038/s41591-022-01925-w. Epub 2022 Aug 11.
7
P-tau217 in Alzheimer's disease.
Clin Chim Acta. 2022 Jun 1;531:100-111. doi: 10.1016/j.cca.2022.03.018. Epub 2022 Mar 24.
8
Overview of tau PET molecular imaging.
Curr Opin Neurol. 2022 Apr 1;35(2):230-239. doi: 10.1097/WCO.0000000000001035.
9
Changes in retinal microvasculature and retinal layer thickness in association with apolipoprotein E genotype in Alzheimer's disease.
Sci Rep. 2021 Jan 19;11(1):1847. doi: 10.1038/s41598-020-80892-z.
10
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.
Neurology. 2019 Oct 22;93(17):e1647-e1659. doi: 10.1212/WNL.0000000000008081. Epub 2019 Aug 1.
Zotero 插件